Vymedic

Vymedic

Early Stage

Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.

Scientifically proven broad-spectrum antiviral beats industry-leading treatments in the suppression of flu, colds and common viruses.

Overview

Raised to Date: Raised: $202,770

Total Commitments ($USD)

Platform

Netcapital

Start Date

09/24/2020

Close Date

03/23/2021

Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment

$100

Security Type

Equity - Common

Series

Pre-Seed

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Price Per Share

$5.00

Pre-Money Valuation

$20,000,000

Rolling Commitments ($USD)

Status
Funded
Reporting Date

03/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$1,127

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2020

Industry

Healthcare & Pharmaceuticals

Tech Sector

Biotech

Distribution Model

B2C

Margin

High

Capital Intensity

High

Location

Englewood, Colorado

Business Type

Growth

Vymedic, with a post-money valuation of $23 million, is raising crowdfunding on NetCapital. The company has manufactured Vymune, a broad-spectrum antiviral, that beats other treatments in the suppression of influenza. Vymune is not strain-specific and activates the immune system against the illness. Cynthia Winning founded Vymedic in March 2020. The current crowdfunding round has a minimum goal of $10,000 and a maximum goal of $1,070,000, and the proceeds will be used for hiring, manufacturing, and marketing. The product of Vymedic is patented, natural, and made up of amino acids, bioflavonoids, and co-factors. It is safe to use for children, elderly, pregnant women, and immunosuppressed individuals.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-46,788

$-45,688

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$2,032

$3,105

Accounts Receivable

$0

$0

Total Assets

$2,032

$3,105

Short-Term Debt

$0

$0

Long-Term Debt

$0

$0

Total Liabilities

$0

$0

Financials as of: 09/24/2020
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Founder Profile

Vymedic Founder Cynthia Winning on Antiviral Solutions

In the age of COVID-19, broad-spectrum, OTC, antivirals could change the game. Under the leadership of Cynthia Winning, the team at Vymedic is aiming to disrupt the OTC wellness space with a new immune support tablet. We sat down with Cynthia to discuss what inspired her to build the company, her vision for the future of the space, and more-


Read Founder Interview

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Vymedic on NetCapital
Platform: Netcapital
Security Type: Equity - Common
Valuation: $20,000,000
Price per Share: $5.00

Follow company

Follow Vymedic on NetCapital

Buy Vymedic's Deal Report

Warning: according to the close date for this deal, Vymedic may no longer be accepting investments.

Vymedic Deal Report

Get KingsCrowd’s comprehensive report on Vymedic including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Vymedic is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Vymedic deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge